Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 683

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Open access
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)·2016·Diabetologia
DOI 10.1007/s00125-016-3902-y
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-016-3902-y

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 111

  1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G (2010) A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53:372–384 · DOI · Paper page
  2. Bellentani S, Saccoccio G, Masutti F et al (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112–117 · DOI · Paper page
  3. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285 · DOI · Paper page
  4. Younossi ZM, Stepanova M, Negro F et al (2012) Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 91:319–327 · DOI · Paper page
  5. Fracanzani AL, Valenti L, Bugianesi E et al (2008) Risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48:792–798 · DOI · Paper page
  6. Marchesini G, Mazzotti A (2015) NAFLD incidence and remission: only a matter of weight gain and weight loss? J Hepatol 62:15–17 · DOI
  7. Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005–2023 · DOI · Paper page
  8. Barrera F, George J (2014) The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis 18:91–112 · DOI
  9. Gerber L, Otgonsuren M, Mishra A et al (2012) Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther 36:772–781 · DOI
  10. Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10:330–344 · DOI · Paper page
  11. Valenti L, Al-Serri A, Daly AK et al (2010) Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51:1209–1217 · DOI · Paper page
  12. Valenti L, Alisi A, Galmozzi E et al (2010) I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52:1274–1280 · DOI · Paper page
  13. Nobili V, Donati B, Panera N et al (2014) A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 58:632–636 · DOI
  14. Kleiner DE, Brunt EM (2012) Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 32:3–13 · DOI · Paper page
  15. Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321 · DOI · Paper page
  16. Bedossa P, Pathology Consortium FLIP (2014) Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60:565–575 · DOI · Paper page
  17. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, NASH Clinical Research Network (CRN) (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:810–820 · DOI · Paper page
  18. Brunt EM, Kleiner DE, Wilson LA et al (2009) Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 49:809–820 · DOI · Paper page
  19. Alkhouri N, De Vito R, Alisi A et al (2012) Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol 57:1312–1318 · DOI
  20. Saadeh S, Younossi ZM, Remer EM et al (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745–750 · DOI · Paper page
  21. Fishbein M, Castro F, Cheruku S et al (2005) Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 39:619–625 · DOI · Paper page
  22. Ryan CK, Johnson LA, Germin BI, Marcos A (2002) One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 8:1114–1122 · DOI · Paper page
  23. Fedchuk L, Nascimbeni F, Pais R et al (2014) Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 40:1209–1222 · DOI · Paper page
  24. Machado MV, Cortez-Pinto H (2013) Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58:1007–1019 · DOI · Paper page
  25. European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado (2015) EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63:237–264 · DOI · Paper page
  26. Cusi K, Chang Z, Harrison S et al (2014) Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 60:167–174 · DOI · Paper page
  27. Vuppalanchi R, Jain AK, Deppe R et al (2014) Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12:2121–2130, e2121-2122 · DOI · Paper page
  28. Guha IN, Parkes J, Roderick P et al (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47:455–460 · DOI · Paper page
  29. McPherson S, Anstee QM, Henderson E, Day CP, Burt AD (2013) Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 25:652–658 · DOI
  30. Wong VW, Vergniol J, Wong GL et al (2010) Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51:454–462 · DOI · Paper page
  31. Castera L, Foucher J, Bernard PH et al (2010) Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51:828–835 · DOI · Paper page
  32. Petta S, Vanni E, Bugianesi E et al (2015) The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 35:1566–1573 · DOI
  33. Vajro P, Lenta S, Socha P et al (2012) Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 54:700–713 · DOI · Paper page
  34. Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P (2013) A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 58:1218–1229 · DOI
  35. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A (2013) Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 5:1544–1560 · DOI · Paper page
  36. Alberti A, Vario A, Ferrari A, Pistis R (2005) Review article: chronic hepatitis C—natural history and cofactors. Aliment Pharmacol Ther 22(Suppl 2):74–78 · DOI
  37. Koliaki C, Szendroedi J, Kaul K et al (2015) Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 21:739–746 · DOI · Paper page
  38. Yki-Järvinen H (2014) Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2:901–910 · DOI · Paper page
  39. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM (2015) Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62:1148–1155 · DOI · Paper page
  40. Pais R, Charlotte F, Fedchuk L et al (2013) A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 59:550–556 · DOI · Paper page
  41. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44–52 · DOI · Paper page
  42. Frith J, Day CP, Robinson L, Elliott C, Jones DE, Newton JL (2010) Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 52:112–116 · DOI
  43. Caldwell SH, Crespo DM (2004) The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40:578–584 · DOI · Paper page
  44. Gomez-Ambrosi J, Silva C, Galofre JC et al (2012) Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) 36:286–294 · DOI · Paper page
  45. Chang Y, Ryu S, Suh BS, Yun KE, Kim CW, Cho SI (2012) Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes (Lond) 36:1187–1194 · DOI
  46. Gomez-Ambrosi J, Catalan V, Rodriguez A et al (2014) Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care 37:2813–2821 · DOI
  47. Ghouri N, Preiss D, Sattar N (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52:1156–1161 · DOI · Paper page
  48. Loomba R, Abraham M, Unalp A et al (2012) Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56:943–951 · DOI · Paper page
  49. Armstrong MJ, Adams LA, Canbay A, Syn WK (2014) Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59:1174–1197 · DOI · Paper page
  50. Ortiz-Lopez C, Lomonaco R, Orsak B et al (2012) Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35:873–878 · DOI · Paper page
  51. Llaurado G, Sevastianova K, Sadevirta S et al (2015) Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. J Clin Endocrinol Metab 100:607–616 · DOI
  52. Anderwald C, Bernroider E, Krssak M et al (2002) Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 51:3025–3032 · DOI
  53. Haflidadottir S, Jonasson JG, Norland H et al (2014) Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 14:166 · DOI
  54. Schwimmer JB, Behling C, Newbury R et al (2005) Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42:641–649 · DOI · Paper page
  55. Oni ET, Agatston AS, Blaha MJ et al (2013) A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 230:258–267 · DOI · Paper page
  56. Bhatia LS, Curzen NP, Calder PC, Byrne CD (2012) Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33:1190–1200 · DOI · Paper page
  57. Calori G, Lattuada G, Ragogna F et al (2011) Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 54:145–152 · DOI · Paper page
  58. Pacifico L, Chiesa C, Anania C, De Merulis A, Osborn JF, Romaggioli S et al (2014) Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol 20:9055–9071
  59. Wong RJ, Cheung R, Ahmed A (2014) Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59:2188–2195 · DOI · Paper page
  60. Musso G, Gambino R, Tabibian JH et al (2014) Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 11, e1001680 · DOI · Paper page
  61. Targher G, Bertolini L, Chonchol M et al (2010) Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 53:1341–1348 · DOI
  62. Kim NH, Park J, Kim SH et al (2014) Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100:938–943 · DOI
  63. Hazlehurst JM, Tomlinson JW (2013) Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 169:R27–R37 · DOI
  64. Bugianesi E, Gentilcore E, Manini R et al (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082–1090 · DOI · Paper page
  65. Zelber-Sagi S, Kessler A, Brazowsky E et al (2006) A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4:639–644 · DOI · Paper page
  66. Dufour JF, Oneta CM, Gonvers JJ et al (2006) Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 4:1537–1543 · DOI · Paper page
  67. Ratziu V, Giral P, Jacqueminet S et al (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135:100–110 · DOI · Paper page
  68. Haukeland JW, Konopski Z, Eggesbo HB et al (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44:853–860 · DOI · Paper page
  69. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA (2009) Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49:80–86 · DOI · Paper page
  70. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ (2009) The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2:157–163 · DOI
  71. Promrat K, Kleiner DE, Niemeier HM et al (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:121–129 · DOI · Paper page
  72. Ratziu V, Charlotte F, Bernhardt C et al (2010) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51:445–453 · DOI · Paper page
  73. Zein CO, Yerian LM, Gogate P et al (2011) Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54:1610–1619 · DOI · Paper page
  74. Lavine JE, Schwimmer JB, Van Natta ML et al (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305:1659–1668 · DOI · Paper page
  75. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:956–965 · DOI · Paper page
  76. Valenti L, Fracanzani AL, Dongiovanni P et al (2014) A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 20:3002–3010 · DOI
  77. Takeshita Y, Takamura T, Honda M et al (2014) The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 57:878–890 · DOI
  78. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M, EPE-A Study Group (2014) No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 147:377–384.e1 · DOI · Paper page
  79. Loomba R, Sirlin CB, Ang B et al (2015) Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61:1239–1250 · DOI · Paper page
  80. Armstrong MJ, Gaunt P, Aithal GP et al (2015) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690 · DOI · Paper page
  81. Zelber-Sagi S, Ratziu V, Oren R (2011) Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 17:3377–3389 · DOI · Paper page
  82. Boden G (2009) High- or low-carbohydrate diets: which is better for weight loss, insulin resistance, and fatty livers? Gastroenterology 136:1490–1492 · DOI
  83. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE (2012) Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379:2243–2251 · DOI · Paper page
  84. Liangpunsakul S, Chalasani N (2012) What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol 107:976–978 · DOI
  85. Kwon HK, Greenson JK, Conjeevaram HS (2014) Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int 34:129–135 · DOI
  86. Dunn W, Sanyal AJ, Brunt EM et al (2012) Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 57:384–391 · DOI · Paper page
  87. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972–1978 · DOI · Paper page
  88. Saab S, Mallam D, Cox GA 2nd, Tong MJ (2014) Impact of coffee on liver diseases: a systematic review. Liver Int 34:495–504 · DOI
  89. Keating SE, Hackett DA, George J, Johnson NA (2012) Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 57:157–166 · DOI · Paper page
  90. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al (2015) Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367–78.e5, quiz e14-e15 · DOI · Paper page
  91. Rodriguez B, Torres DM, Harrison SA (2012) Physical activity: an essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol 9:726–731 · DOI
  92. Adams LA, Sanderson S, Lindor KD, Angulo P (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42:132–138 · DOI · Paper page
  93. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L, American Association for the Study of Liver Diseases, United States Food and Drug Administration (2015) Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology 61:1392–1405 · DOI · Paper page
  94. Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L (2014) Systematic review with meta-analysis: non-alcoholic steatohepatitis—a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 39:3–14 · DOI
  95. Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G (2014) The role of medications for the management of patients with NAFLD. Clin Liver Dis 18:73–89 · DOI
  96. Ratziu V, Goodman Z, Sanyal A (2015) Current efforts and trends in the treatment of NASH. J Hepatol 62:S65–S75 · DOI · Paper page
  97. Bhalla K, Hwang BJ, Dewi RE et al (2012) Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 5:544–552 · DOI
  98. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE (2012) Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 97:2347–2353 · DOI
  99. Hoofnagle JH, Van Natta ML, Kleiner DE et al (2013) Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 38:134–143 · DOI
  100. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T (2010) Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 341:c5702 · DOI · Paper page
  101. Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J (2012) Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56:944–951 · DOI · Paper page
  102. Valenti L, Fracanzani AL, Dongiovanni P et al (2007) Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case–control study. Am J Gastroenterol 102:1251–1258 · DOI · Paper page
  103. Nobili V, Alisi A, Raponi M (2009) Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 15:6017–6022 · DOI
  104. Mitchel EB, Lavine JE (2014) Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 40:1155–1170 · DOI
  105. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P (2009) The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58:1538–1544 · DOI · Paper page
  106. Schauer PR, Bhatt DL, Kirwan JP et al (2014) Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 370:2002–2013 · DOI · Paper page
  107. Lassailly G, Caiazzo R, Buob D et al (2015) Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149:377–388 · DOI · Paper page
  108. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141:1249–1253 · DOI · Paper page
  109. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y (2014) Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12:394–402, e391 · DOI
  110. Heuer M, Kaiser GM, Kahraman A et al (2012) Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 86:107–113 · DOI
  111. Sebagh M, Samuel D, Antonini TM et al (2012) Twenty-year protocol liver biopsies: invasive but useful for the management of liver recipients. J Hepatol 56:840–847 · DOI

Cited by

Metadata

Authors
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO)
Venue
Diabetologia
Publisher
Springer Science and Business Media LLC
Published
2016-04-07
Volume
59
Issue
6
Pages
1121-1140
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
DOI
10.1007/s00125-016-3902-y
OpenAlex
W4233179469
Cited by
683
References
37
FWCI
31.89
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.